Get to know our clinical trials
A Phase III, randomized, open-label, sponsor-blinded, multicenter clinical trial of rilvegostomig in combination with bevacizumab, with or without tremelimumab, as first-line treatment in patients with advanced hepatocellular carcinoma.
THE OBJECTIVE OF THIS CLINICAL TRIAL IS TO GATHER MORE INFORMATION ON THE EFFICACY AND SAFETY OF RILVEGOSTOMIG IN COMBINATION WITH BEVACIZUMAB, WITH OR WITHOUT TREMELIMUMAB, COMPARED TO THE STANDARD OF CARE (ATEZOLIZUMAB IN COMBINATION WITH BEVACIZUMAB), AS WELL AS TO BETTER UNDERSTAND THE DISEASE BEING STUDIED AND THE ASSOCIATED HEALTH ISSUES
Technical Summary
- A PHASE III, RANDOMIZED, OPEN-LABEL, SPONSOR-BLINDED, MULTICENTER TRIAL OF RILVEGOSTOMIB IN COMBINATION WITH BEVACIZUMAB, WITH OR WITHOUT TREMELIMUMAB, AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (ARTEMIDE-HCC01).
- Code EudraCT: 2024-518210-81-00
- Protocol number: D7029C00001
- Promoter: Astrazeneca
- Molecule/Drug: Rilvegostomig, bevacizumab
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.